

PRESS RELEASE

31 August 2023 08:00:00 CEST

New number of shares and votes in Senzime AB (publ)

As previously announced, Senzime carried out a directed share issue on August 24, 2023. The share issue consisted of a total of 12,500,000 shares. The first part of the share issue, 11,362,500 shares, has been subscribed, paid for, and registered. The number of shares and votes in Senzime has therefore increased, and as of August 31, 2023, the total number of shares in Senzime amounts to 98,985,114 (previously 87,622,614 shares), with one vote each. The share capital amounts to SEK 12,373,139.25 (previously SEK 10,952,826.75).

In accordance with the prior press release and separate notice, a general meeting will take place on September 20, 2023. During the general meeting, a directed share issue of an additional 1,137,500 shares to the company's chairman of the board is proposed under the same terms. However, these 1,137,500 shares have not yet been subscribed to or paid for.

As of August 31, 2023, Senzime holds no treasury shares.

For further information, please contact:

Philip Siberg, CEO of Senzime AB

Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO

Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at [senzime.com](https://www.senzime.com).

This information is information that Sensime is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-08-31 08:00 CEST.

Attachments

New number of shares and votes in Sensime AB (publ)